Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viral Testing Systems

This article was originally published in The Gray Sheet

Executive Summary

Firm's Fluorognost HIV-1 immunofluorescent assay (IFA) test is successful in detecting a "set of African AIDS virus variants" termed "Subtype O," VTS announces. At the recent International Conference on AIDS in Yokohama, Japan, researchers from the Centers for Disease Control and Prevention investigated the performance of nine FDA-licensed diagnostic tests to detect the new "Subtype O" strain. Only three of the tests, including VTS' Fluorognost, were able to identify specimens 100% of the time as positive, the firm says. The Fluorognost IFA was the first HIV-1 diagnostic to be marketed as both a screening and confirmation test ("The Gray Sheet" March 2, 1992, p. 9)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel